New drugs for type 2 diabetes have been approved recently and have given physicians more options for treatment. ... thought. Our story looks at the risks and benefits of prescribing new drugs in patients with diabetes and how to determine which
Drawing lines. Envision a scenario: Milt is 87. Over the years he's developed diabetes, high blood pressure, arthritis, lumbago (back pain), hearing loss, too many moles to count, and high
They are like diet and exercise for severe uncontrolled diabetes, necessary but inadequate when what we need is a strong dose of insulin to drive down the glucose quickly.
More attention is paid to those with chronic conditions like heart failure, diabetes, or emphysema.
Liraglutide (Victoza) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. ... It is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise, and pancreatitis
Weight loss by healthy means is among the most important ways of reducing risk for diabetes and heart disease. ... A diet cannot be good for health unless it reduces the risk of heart disease and diabetes.
Essentially, there are three areas where safety data was updated: liver enzymes, memory impairment and diabetes. ... You can see my post "Statins Don't Cause Diabetes" for all the details.
A fixed-dose combination pill of sitagliptin and simvastatin (Juvisync). The first product to combine a type 2 diabetes drug and a statin, it is currently available in dosage strengths for ... Prescribing information for the drug informs doctors of the
For example, the chance that a patient is being seen just for diabetes is low. ... Many people with diabetes also have hypertension or hypercholesterolemia.“ Having a guideline recommendation that addresses a single disease condition may not be enough
The drug is contraindicated in patients with general obesity and is not approved for use in patients with HIV-related lipodystrophy or metabolic disease, including diabetes mellitus and hypertriglyceridemia, without concurrent